NetworkNewsBreaks – Delic Holdings Corp. (CSE: D
Post# of 135
(Total Views: 170)
Posted On: 02/18/2022 2:04:25 PM
NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18% indicated that the prescribed drugs worsened their condition or did not improve it at all. Further, 83% of Americans living with anxiety, depression or PTSD “would be open to pursuing alternative treatment proven to be more effective than prescription medication with fewer side effects.” In describing psychedelics, a family of promising medicines, Delic co-founder and CEO Matt Stang highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18% indicated that the prescribed drugs worsened their condition or did not improve it at all. Further, 83% of Americans living with anxiety, depression or PTSD “would be open to pursuing alternative treatment proven to be more effective than prescription medication with fewer side effects.” In describing psychedelics, a family of promising medicines, Delic co-founder and CEO Matt Stang highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)